147 related articles for article (PubMed ID: 32938796)
1. B cell acute lymphoblastic leukemia cells mediate RANK-RANKL-dependent bone destruction.
Rajakumar SA; Papp E; Lee KK; Grandal I; Merico D; Liu CC; Allo B; Zhang L; Grynpas MD; Minden MD; Hitzler JK; Guidos CJ; Danska JS
Sci Transl Med; 2020 Sep; 12(561):. PubMed ID: 32938796
[TBL] [Abstract][Full Text] [Related]
2. RANK-Fc: a therapeutic antagonist for RANK-L in myeloma.
Sordillo EM; Pearse RN
Cancer; 2003 Feb; 97(3 Suppl):802-12. PubMed ID: 12548579
[TBL] [Abstract][Full Text] [Related]
3. Increase in expression of receptor activator of nuclear factor kappaB at sites of bone erosion correlates with progression of inflammation in evolving collagen-induced arthritis.
Lubberts E; Oppers-Walgreen B; Pettit AR; Van Den Bersselaar L; Joosten LA; Goldring SR; Gravallese EM; Van Den Berg WB
Arthritis Rheum; 2002 Nov; 46(11):3055-64. PubMed ID: 12428250
[TBL] [Abstract][Full Text] [Related]
4. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
5. Human acute leukemia cells injected in NOD/LtSz-scid/IL-2Rgamma null mice generate a faster and more efficient disease compared to other NOD/scid-related strains.
Agliano A; Martin-Padura I; Mancuso P; Marighetti P; Rabascio C; Pruneri G; Shultz LD; Bertolini F
Int J Cancer; 2008 Nov; 123(9):2222-7. PubMed ID: 18688847
[TBL] [Abstract][Full Text] [Related]
6. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
7. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis.
Romas E; Sims NA; Hards DK; Lindsay M; Quinn JW; Ryan PF; Dunstan CR; Martin TJ; Gillespie MT
Am J Pathol; 2002 Oct; 161(4):1419-27. PubMed ID: 12368214
[TBL] [Abstract][Full Text] [Related]
8. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
9. Achyranthes bidentata extract exerts osteoprotective effects on steroid-induced osteonecrosis of the femoral head in rats by regulating RANKL/RANK/OPG signaling.
Jiang Y; Zhang Y; Chen W; Liu C; Li X; Sun D; Liu Z; Xu Y; Mao X; Guo Q; Lin N
J Transl Med; 2014 Nov; 12():334. PubMed ID: 25471933
[TBL] [Abstract][Full Text] [Related]
10. An Fc-engineered CD19 antibody eradicates MRD in patient-derived
Schewe DM; Alsadeq A; Sattler C; Lenk L; Vogiatzi F; Cario G; Vieth S; Valerius T; Rosskopf S; Meyersieck F; Alten J; Schrappe M; Gramatzki M; Peipp M; Kellner C
Blood; 2017 Sep; 130(13):1543-1552. PubMed ID: 28698205
[TBL] [Abstract][Full Text] [Related]
11. Targeted blockade of immune mechanisms inhibit B precursor acute lymphoblastic leukemia cell invasion of the central nervous system.
Rajakumar SA; Grandal I; Minden MD; Hitzler JK; Guidos CJ; Danska JS
Cell Rep Med; 2021 Dec; 2(12):100470. PubMed ID: 35028611
[TBL] [Abstract][Full Text] [Related]
12. Malignant B-lymphoid cells with bone lesions express receptor activator of nuclear factor-kappaB ligand and vascular endothelial growth factor to enhance osteoclastogenesis.
Shibata H; Abe M; Hiura K; Wilde J; Moriyama K; Sano T; Kitazoe K; Hashimoto T; Ozaki S; Wakatsuki S; Kido S; Inoue D; Matsumoto T
Clin Cancer Res; 2005 Sep; 11(17):6109-15. PubMed ID: 16144909
[TBL] [Abstract][Full Text] [Related]
13. Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone.
Virk MS; Petrigliano FA; Liu NQ; Chatziioannou AF; Stout D; Kang CO; Dougall WC; Lieberman JR
Bone; 2009 Jan; 44(1):160-7. PubMed ID: 18929692
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of hormone and cytokine-stimulated osteoclastogenesis and bone resorption by interleukin-4 and interleukin-13 is associated with increased osteoprotegerin and decreased RANKL and RANK in a STAT6-dependent pathway.
Palmqvist P; Lundberg P; Persson E; Johansson A; Lundgren I; Lie A; Conaway HH; Lerner UH
J Biol Chem; 2006 Feb; 281(5):2414-29. PubMed ID: 16251181
[TBL] [Abstract][Full Text] [Related]
15. Bone destruction in arthritis.
Gravallese EM
Ann Rheum Dis; 2002 Nov; 61 Suppl 2(Suppl 2):ii84-6. PubMed ID: 12379632
[TBL] [Abstract][Full Text] [Related]
16. Osteoclast differentiation by RANKL and OPG signaling pathways.
Udagawa N; Koide M; Nakamura M; Nakamichi Y; Yamashita T; Uehara S; Kobayashi Y; Furuya Y; Yasuda H; Fukuda C; Tsuda E
J Bone Miner Metab; 2021 Jan; 39(1):19-26. PubMed ID: 33079279
[TBL] [Abstract][Full Text] [Related]
17. High frequencies of leukemia stem cells in poor-outcome childhood precursor-B acute lymphoblastic leukemias.
Morisot S; Wayne AS; Bohana-Kashtan O; Kaplan IM; Gocke CD; Hildreth R; Stetler-Stevenson M; Walker RL; Davis S; Meltzer PS; Wheelan SJ; Brown P; Jones RJ; Shultz LD; Civin CI
Leukemia; 2010 Nov; 24(11):1859-66. PubMed ID: 20739953
[TBL] [Abstract][Full Text] [Related]
18. Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma.
Michigami T; Ihara-Watanabe M; Yamazaki M; Ozono K
Cancer Res; 2001 Feb; 61(4):1637-44. PubMed ID: 11245477
[TBL] [Abstract][Full Text] [Related]
19. The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1.
Urushibara M; Takayanagi H; Koga T; Kim S; Isobe M; Morishita Y; Nakagawa T; Löeffler M; Kodama T; Kurosawa H; Taniguchi T
Arthritis Rheum; 2004 Mar; 50(3):794-804. PubMed ID: 15022321
[TBL] [Abstract][Full Text] [Related]
20. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
Zhu L; Wei H; Wu Y; Yang S; Xiao L; Zhang J; Peng B
Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
